Patents by Inventor Robert D. Goldman

Robert D. Goldman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEMS AND METHODS FOR DETERMINING DRUG POTENTCY USING MACHINE LEARNING ALGORITHMS
    Publication number: 20240152730
    Abstract: A system comprising a first expired drug usability device is provided. The first expired drug usability device comprises a first spectrometer and one or more first processors. The first processors are configured to: obtain at least one expired drug machine learning-artificial intelligence (ML-AI) model associated with a pharmaceutical drug; obtain drug expiration information of a sample of the pharmaceutical drug, wherein the drug expiration information comprises spectrometer data associated with using the first spectrometer on the sample; input the drug expiration information into the at least one expired drug ML-AI model to determine usability information associated with the sample of the pharmaceutical drug; and perform one or more actions based on the usability information.
    Type: Application
    Filed: November 8, 2022
    Publication date: May 9, 2024
    Inventors: Dwayne Kurfirst, Neal Shah, Tulsi Patel, Clark D. Peterson, Matthew C. Van Allen, Alan Bachmann, Ajay Behuria, Harpreet Kaur, Robert W. Goldman, Katharine R. Flanagan, Zainab Salahudin, Kamya Menon
  • Biomarker for replicative senescence
    Patent number: 9383357
    Abstract: The present invention provides biomarkers for replicative senescence. In particular, Lamin B1 is provided as a biomarker for replicative senescence.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: July 5, 2016
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Robert D. Goldman, Takeshi Shimi, Stephen A. Adam
  • BIOMARKER FOR REPLICATIVE SENESCENCE
    Publication number: 20140162288
    Abstract: The present invention provides biomarkers for replicative senescence. In particular, Lamin B1 is provided as a biomarker for replicative senescence.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 12, 2014
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Robert D. Goldman, Takeshi Shimi, Stephen A. Adam
  • Use of synthetic peptides to disrupt the cytoskeleton
    Patent number: 5527773
    Abstract: Synthetic peptides corresponding to different regions of the human keratin 1 chain can disassemble preformed keratin intermediate filaments or inhibit filament assembly both in vitro and in vivo. The disruption of keratin filaments may have therapeutic applications in the treatment of epithelial abnormalities.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: June 18, 1996
    Assignee: United States of America
    Inventors: Peter M. Steinert, Robert D. Goldman, John J. DiGiovanna